Quoin Pharmaceuticals Ltd (NASDAQ:QNRX) shares rose 2.2% in premarket trading Tuesday after the late-stage biopharmaceutical company announced positive 9-month clinical results from its pediatric Netherton Syndrome trial and confirmed the enrollment of three additional patients.
The company reported that the first pediatric patient in the study achieved fully healed skin after nine months of treatment with its investigational therapy QRX003. The patient’s Investigator’s Global Assessment score improved dramatically — from the most severe rating of 4 at baseline to 0, indicating completely clear skin.
Additionally, the patient’s pruritus (itching) score improved from 5 to 0, and the child was able to sleep through the night without sedating medication for the first time. The patient also no longer requires previous treatments such as antibiotics, antivirals, antihistamines, and glucocorticoids.
Quoin has now recruited three additional pediatric participants — two from Austria and one from Ireland — into the investigator-led study. These patients will receive twice-daily, whole-body applications of QRX003 for an initial 12-week period before entering a long-term extension protocol until regulatory approval.
“The achievement of, and continued retention of, both fully healed skin and the complete elimination of pruritus in the first pediatric subject is a testament to the clinical benefit of QRX003 in NS,” said CEO Michael Myers. “Treatment with QRX003 has truly been completely life transforming for this little girl.”
The company believes the new patient data will further reinforce the growing clinical evidence supporting QRX003 as a promising treatment option for Netherton Syndrome.